364 results on '"Smyth, John F."'
Search Results
2. WWOX: A Candidate Tumor Suppressor Gene Involved in Multiple Tumor Types
3. Supplementary Figure 5 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
4. Data from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
5. Supplementary Methods, Legends for Figures 1-5 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
6. Supplementary Figure 3 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
7. Supplementary Table 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
8. Supplementary Figure 4 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
9. Supplementary Figure Legends 1-4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
10. Supplementary Figure 2 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
11. Supplementary Figure 3 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
12. Supplementary Table 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
13. Supplementary Figure 4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
14. Data from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
15. Supplementary Figure 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
16. Supplementary Figure 1 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3
17. Supplementary Figure 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
18. Types of Immunodeficiency in Mice
19. Studies in Tumor Cell Biology
20. Association of galectin-3 expression with melanoma progression and prognosis
21. Corticosteroids, Dopamine Antagonists, and Other Drugs
22. Communicating with Cancer Patients
23. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
24. Factors influencing the cellular accumulation of SN-38 and camptothecin
25. Disclosing gaps between supportive and palliative care—the past 20 years
26. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo
27. Corticosteroids, dopamine antagonists and other drugs
28. Endometrioid Epithelial Ovarian Cancer: 20 Years of Prospectively Collected Data From A Single Center
29. Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo
30. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography
31. Creating a unified Europe: losing identity and visibility for a greater profit?
32. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells
33. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer
34. The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma
35. Role of TGFα stimulation of the ERK, PI3 kinase and PLCγ pathways in ovarian cancer growth and migration
36. A phase I and pharmacology study of GR63178A, a water-soluble analogue of mitoquidone
37. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins
38. Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology
39. Chromatographic characterisation of six human metabolites of the new anticancer drug GR63 178A
40. A functional approach to the identification of ovarian cancer tumour suppressor genes located on chromosome 11
41. Cancer Genetics and Cell and Molecular Biology*: Is This the Way Forward?
42. High-Performance Liquid Chromatographic Technique for the Simultaneous Determination of Lactone and Hydroxy Acid Forms of Camptothecin and SN-38 in Tissue Culture Media and Cancer Cells
43. Optimising Antiemesis In Cancer Chemotherapy: Efficacy Of Continuous Versus Intermittent Infusion Of High Dose Metoclopramide In Emesis Induced By Cisplatin
44. Tamoxifen As Primary Treatment Of Breast Cancer In Elderly Or Frail Patients: A Practical Management
45. Euro Exams
46. Interferons and Lung Cancer: Preclinical and Clinical Investigations
47. A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer
48. WWOX: A candidate tumor suppressor gene involved in multiple tumor types
49. The clinical pharmacology of mitozantrone
50. Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.